Targeted
 Protein
Degradation

[ News ]

2021.06.17
UBiECNE has signed a seed round share subscription agreement and renewed a collaboration agreement with D. Western Therapeutics Institute, Inc.
2021.06.17
Notice of Transition to a Company with a Board of Directors and a Company with Corporate Auditors, Election of Directors, Election of Corporate Auditors and Change of Representative Director
2021.03.31
UBiENCE has completed its role as a supporting company for ACT-MS with NIHS.
2020.10.01
An interview about UBIENCE was published in the October 1, 2020 issue of AnswersNews.
2020.09.11
An article about UBiENCE was published in the The Chemical Daily issued on September 11, 2020.
2020.08.26
An article about UBiENCE was published in the Nikkei Money Special Report in Nihon Keizai Shimbun issued on August 26, 2020.
2020.08.10
An article about UBiENCE was published on the column of "Venture tanbou" in Nikkei Biotechnology and Business issued on August 10, 2020.
2019.11.15
UBiENCE has been selected for the second phase of the Ministry of Economy, Trade and Industry's Intellectual Property Acceleration Program for 2019.
2019.10.16
UBiENCE Announces Collaboration Research Agreement With D. Western Therapeutics Institute for Ophthalmology.
2018.09.13
UBiENCE is adopted by ACT-MS along with National Institute of Health Sciences and Eisai.

Our Science

SNIPER: Specific and Non-genetic IAP-dependent Protein ERaser

IAPs are frequently overexpressed in tumor cells,
which is involved in resistance to tumor therapy

Company Overview

Name
UBiENCE Inc.
Address
8F Nihonbashi Life Science Building7 1-9-10 Nihonbashi-horidomecho, Chuo-ku, Tokyo 103-0012, JAPAN
Business Summary
Discovery and Development of Pharmaceutical Compounds
Established
April 20, 2018
Capitalization
227,320,000Yen
Employees
3
URL
https://www.ubience.com/
Fiscal Year
December
Board of Directors

President Yasuhiro IWATA

Director Nobuyuki TAKAHASHI

Director, Co-founder Hirobumi TAKEUCHI

Company Auditors
Atsuko SUYAMA